Stargardt macular degeneration

What it is, symptoms and effects

From: MedlinePlus Genetics, National Library of Medicine

Stargardt macular degeneration is a genetic eye disorder that causes progressive vision loss. This disorder affects the retina, the specialized light-sensitive tissue that lines the back of the eye. Specifically, Stargardt macular degeneration affects a small area near the center of the retina called the macula. The macula is responsible for the type of vision needed for detailed tasks such as reading, driving, and recognizing faces. In most people with Stargardt macular degeneration, a fatty yellow pigment called lipofuscin builds up in cells underlying the macula. Over time, the abnormal accumulation of this substance can damage cells that are critical for clear vision. People with Stargardt macular degeneration have problems with night vision that can make it difficult to navigate in low light. Some affected individuals also have impaired color vision. The signs and symptoms of Stargardt macular degeneration typically appear in late childhood to early adulthood and worsen over time.

Inheritance

From: MedlinePlus Genetics, National Library of Medicine

Autosomal recessive; Autosomal dominant

Understanding terms used in the source

These definitions explain medical words used above. A definition is not evidence that another condition is present, and it does not predict how a symptom will develop. Ask the clinician which terms apply to the actual examination or test result.

Macular degeneration

A nonspecific term denoting degeneration of the retinal pigment epithelium and/or retinal photoreceptor cells of the macula lutea.

Progressive

Applies to a disease manifestation that increases in scope or severity over the course of time, i.e., that worsens with age.

Affected

This term applies to a family member who is diagnosed with the same condition as the individual who is the primary focus of investigation (the proband).

When it may begin

From: MedlinePlus Genetics, National Library of Medicine

The signs and symptoms of Stargardt macular degeneration typically appear in late childhood to early adulthood and worsen over time.

Inheritance in the source

From: MedlinePlus Genetics, National Library of Medicine

Autosomal recessive; Autosomal dominant

Which doctor should you see?

The suggested department for discussing Stargardt macular degeneration is Ophthalmology, with a ophthalmologist as the relevant type of clinician. Ophthalmologist; paediatric services for children as appropriate.

Additional services that may be relevant, depending on the findings, include: Clinical Genetics.

This is an editorial referral starting point. The appropriate clinic depends on the person’s age, symptoms, previous diagnosis and local services. The first clinician can decide whether another specialty or a team is needed; a department label does not confirm the diagnosis.

How to prepare for an assessment

Bring a short timeline of the main symptoms: when they first appeared, whether they are constant or episodic, what seems to change them, and how they affect daily activities. Include previous reports, discharge summaries, current medicines and supplements, allergies, and any relevant family history. A dated record is more useful than trying to match every feature in an online article.

Ask the clinician what is already established and what remains uncertain. If a test is suggested, ask what question it answers, what its limitations are and how the result would change the next step. The information here is not an instruction to arrange every possible test. In children, bring growth, developmental and school information if it is relevant to the concern.

• Which part of the eye or visual pathway is affected?
• What change in vision requires immediate contact with the eye service?
• What are the aims and alternatives of any proposed eye treatment?

Treatment discussions and follow-up

The material gathered for this draft does not provide a complete condition-specific treatment pathway for Stargardt macular degeneration. That gap does not mean that treatment is unavailable. A clinician needs to establish the diagnosis and review current guidance before recommending medicines, procedures, rehabilitation or other support.

Before leaving the appointment, clarify the next review date, who will communicate results, and whom to contact if the situation changes. Discuss difficulties with sleep, work, school, mobility, eating or emotional wellbeing when these are relevant. Practical support may require coordination between the treating clinician and other services.

The collected references do not establish a complete prevention or long-term outlook section for this entry. Missing information should not be interpreted as proof that prevention is impossible or that a particular outcome is inevitable. Ask what is known for the exact subtype, stage and personal circumstances, and which uncertainties remain.

When to seek emergency help

Severe breathing difficulty, collapse, new stroke-like symptoms, a seizure that is prolonged or repeated without recovery, uncontrolled major bleeding, or an immediate risk of self-harm require emergency help. In India, call 112 or reach the nearest emergency department. This is a general, non-exhaustive warning list; it is not a condition-specific triage tool.

Questions about the diagnosis and everyday life

If Stargardt macular degeneration is only suspected, ask what other explanations are being considered and what would distinguish them. Similar symptoms can occur in different conditions. A clinician should interpret the pattern of findings, the examination and any investigations together; reading a list of features cannot establish whether this diagnosis fits.

If the diagnosis is already confirmed, ask which features are relevant to you and which are only possible features described in a broader group. Check whether changes in daily activities are needed, whether another health problem affects the plan, and whether a written summary would help other clinicians understand your care.

When comparing care options, ask about the expected benefit, the likely time needed to assess improvement, the burdens of treatment, and reasonable alternatives. If costs, travel or availability make a plan difficult, raise this during the consultation so the team can discuss a workable follow-up arrangement. Do not assume that a specialist test or treatment described in an overseas source is routinely available locally.